Fundraising Fox
/Companies
Sign in

Dbv Technologies

Châtillon, FR · France corporation · 2 known investors

Find your way into Dbv Technologies

Each arrow is one introduction. Sign up to fill in the first one.

133 people can intro you to Virginie

Ask Sylvain Jauze to introduce you to Virginie Boucinha

You →Sylvain · together at Paris School of Business →Virginie

95 people can intro you to Daniel

Ask Jamie Chen to introduce you to Daniel Tasse

You →Jamie · together at Dbv Technologies →Daniel

Sign up to find every way you can get introduced to Dbv Technologies

  • Your email: who you already know at Dbv Technologies, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Dbv Technologies team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

DBV Technologies develops the VIASKIN® patch, a non-invasive, skin-based immunotherapy technology for treating food allergies and other immunological disorders. The company is investigating applications including allergy treatment and vaccine delivery through epicutaneous immunotherapy.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

PMPharis Mohideen
Pharis MohideenChief Medical Officer
DT
Daniel TasseCEO / Directeur GeneralDaniel Tasse is an Executive Officer and Director at DBV Technologies, which develops VIASKIN®, a skin-based immunotherapy patch for treating food allergies and other immunological conditions. He has held leadership roles across pharmaceutical, medical device, and healthcare delivery businesses operating internationally.
VBVirginie Boucinha
Virginie BoucinhaChief Financial OfficerVirginie Boucinha has held finance and pharmaceutical industry roles across multiple functions at Sanofi, including audit, controlling, treasury, CFO, sales, product management, and business intelligence, as well as serving as Chief of Staff to the Group CEO and leading global transformation initiatives. She has developed her career in France, the United States, Morocco, and India.

Board

MF
Mailys FerrereBoard director
MG
Michael GollerBoard director
RM
Ravi Madduri RaoBoard director
DG
Daniele Guyot-CaparrosBoard director
DS
Daniel SolandBoard director
AN
Adora NduBoard director
JO
Julie O'NeillBoard director
MD
Michel de RosenBoard director
TE
Timothy E. MorrisBoard director

Investors · 2

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$306.9M disclosed across 1 round · 2025

▶$306.9MraisedApr 2025 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mailys FerrereDirector
  • Ravi Madduri RaoDirector
  • Daniele Guyot-CaparrosDirector
  • Pharis MohideenExecutive Officer
  • Daniel SolandDirector
  • Adora NduDirector
  • Julie O'NeillDirector
  • Daniel TasseExecutive Officer, Director
  • Virginie BoucinhaExecutive Officer
  • Michel de RosenDirector
  • Timothy E. MorrisDirector
  • Michael GollerDirector
Offering amount
$306.9M
Amount sold
$306.9M
Sales commissions
$18.4M
Placement agents
Van Lanschot Kempen NV, Van Lanschot Kempen (USA) Inc., LifeSci Capital LLC
First sale
Apr 2025
Incorporated
Corporation, France
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Dbv Technologies went on to found or lead other companies.

David SchilanskyDeputy CEO (directeur général délégué)Founded One Biosciences +1Daniel TasseExecutive Officer, DirectorFounded AlcrestaCharles RubanChief Operating OfficerFounded Verdot Biotechnologies

Related companies · 4

TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.

Companies working in the same space as Dbv Technologies.

Frequently asked questions

What does Dbv Technologies do?
DBV Technologies develops the VIASKIN® patch, a non-invasive, skin-based immunotherapy technology for treating food allergies and other immunological disorders. The company is investigating applications including allergy treatment and vaccine delivery through epicutaneous immunotherapy.
Who are Dbv Technologies's investors?
Dbv Technologies's investors include Karista, Sofinnova Partners.
How much funding has Dbv Technologies raised?
Dbv Technologies has disclosed $306.9M raised across 1 round.
Where is Dbv Technologies headquartered?
Dbv Technologies is headquartered in Châtillon, FR.